SCHEMBL3384476

SCHEMBL3384476

C[C@@H]1CCCN1CCCOc1ccc2c(n1)CCN(c1ccc(C(N)=O)cn1)C2

nearest known ligand 0.41

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 12/20 0.41
OPRM1 P35372 6/20 0.40
OPRD1 P41143 6/20 0.40
OPRK1 P41145 5/20 0.40
HTR3A P46098 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3386217 0.90 HRH3 (0.41) HRH3
SCHEMBL3385401 0.90 HRH3 (0.41) HRH3
SCHEMBL3434200 0.85 OPRM1 (0.48) HRH3OPRM1OPRD1OPRK1
SCHEMBL3384977 0.85 OPRM1 (0.47) HRH3OPRM1OPRD1OPRK1
SCHEMBL3387528 0.81 HRH3 (0.42) HRH3HTR3A
SCHEMBL3389982 0.81 HRH3 (0.42) HRH3HTR3A
SCHEMBL3921930 0.81 HRH3 (0.42) HRH3HTR3A
SCHEMBL3385220 0.79 HRH3 (0.42) HRH3HTR3A
SCHEMBL3919717 0.79 HRH3 (0.42) HRH3HTR3A
SCHEMBL3384991 0.79 HRH3 (0.40) HRH3HTR3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1756104-B1 TETRAHYDRONAPHTHYRIDINE DERIVATIVES USEFUL AS HISTAMINE H3 RECEPTOR LIGANDS PFIZER LTD (GB) 2010-12-15 EP claimed
US-20090258861-A1 Tetrahydronaphthyridine Derivatives LUNN GRAHAM 2009-10-15 US claimed
US-7557121-B2 Tetrahydronaphthyridine derivatives PFIZER INC (US) 2009-07-07 US claimed
US-20050256135-A1 Tetrahydronaphthyridine derivatives LUNN GRAHAM 2005-11-17 US claimed
EP-1756104-B1 TETRAHYDRONAPHTHYRIDINE DERIVATIVES USEFUL AS HISTAMINE H3 RECEPTOR LIGANDS PFIZER LTD (GB) 2010-12-15 EP disclosed
US-20090258861-A1 Tetrahydronaphthyridine Derivatives LUNN GRAHAM 2009-10-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256135-A1 Tetrahydronaphthyridine derivatives HRH4, HRH3, HRH1 HRH3 2/4885OPRM1 244/4885OPRD1 134/4885
US-20090258861-A1 Tetrahydronaphthyridine Derivatives HRH4, HRH3, HRH1 HRH3 2/4885OPRM1 244/4885OPRD1 134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.